On September 29 2008, Sanofi Pasteur, the vaccines division of Sanofi-Aventis, filed an opposition against the application by Getz Bros Philippines for the trademark Comaxin, covering pharmaceutical products for the treatment of infections in the upper and lower respiratory tract, ENT, skin and soft tissue, gut infections, osteomylitis, septcoemia, peritonitis and post-op infections in class 5. Sanofi Pasteur claimed that Getz's Comaxin mark was confusingly similar with its own Combaxim mark registered in 2007, covering pharmaceutical preparations in the form of pediatric vaccines.